Novo Nordisk: The Pill That Could Close The Gap With Lilly

Impact · against what's priced in

Novo Nordisk shows strong execution with the rapid adoption of oral Wegovy and a clear path to future growth via CagriSema. While pricing headwinds persist, the scale of oral market penetration provides a significant competitive buffer against Eli Lilly.

NVO+0.60

No priced-in read yet

In context

The capture of 90% of the US oral obesity market with 5 million prescriptions demonstrates rapid adoption and a strong competitive moat.

Read from the article alone

• healthcare
• NVO
• glp 1
• obesity drugs
• oral medication
• pharma
• pipeline
• wegovy
• weight loss

Search tags